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1. Introduction 
The enzyme 17 /I-estradiol dehydrogenase from 
human placenta is inactivated by substrate analogues 
[l-4] and the coenzyme analogue chloroacetyl- 
pyridinio-adenine dinucleotide [5,6]. Nicotinamide- 
[5-bromoacetyl-4-methylimidazole] -dinucleotide 
possesses a reactive bromoacetyl residue in the non 
functional part of the coenzyme analogue [7]. This 
compound reacts with nucleophilic groups of amino- 
acid residues, which are located in the coenzyme 
binding area [8]. 
2. Materials and methods 
The preparation of the coenzyme analogue nicotin- 
amide- [5-bromoacetyl-4-methylimidazole] dinucleo- 
tide [ 14C] carbonyl-labelled in the nicotinamide 
carboxyl group has been reported before [7]. NAD’ 
and NADP’ were purchased from Boehringer 
Mannheim. The purification of 17 fl-estradiol dehy- 
drogenase (EC 1.1.1.62) and the enzyme assay have 
been described previously [9]. The inactivation 
reaction, pH-dependency, were carried out as follows. 
The incorporation of the reactive coenzyme 
analogue was measured by using [r4C] carbonyl 
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nicotinamide- [ 5-bromoacetyl-4-methylimidazole] 
dinucleotide with a specific radioactivity of 0.36 mCi/ 
mmol. 10.2 mg of the inactivator were dissolved in 
0.15 ml 0.6 M Tris-HCl buffer pH 7.2 and added to 
5 ml solution of 2.9 mg enzyme in 0.03 M phosphate 
buffer pH 7.2 containing 20% glycerol. The extent of 
the inactivation at 37’C was measured using the 
enzymatic test [9]. The inactivation reactions were 
done with or without the substrate estradiol at a 
concentration of 1 X 1 0m4 M. At various inactivation 
levels, 1 ml aliquots were precipitated by addition of 
4 ml 10% aquous trichloro acetic acid. This process 
was repeated ten times to remove the not covalently 
bound inactivator. The incorporated radioactivity was 
determined after solving the precipitates in 8 M urea 
buffer. For the identification of labelled amino acids 
3.72 mg of 17 /3-estradiol dehydrogenase in 0.03 M 
phosphate buffer pH 7.2, 20% glycerol were com- 
pletely inactivated in presence of 0.1 mM estradiol by 
addition of nicotinamide-[5-bromoacetyl-Cmethyl- 
imidazole] dinucleotide in 0.6 M Tris-HCl buffer, 
pH 7.2 (resulting concentration of the inactivator 
was 5.8 mM). After removing the excess of the 
inactivator by dialysis against 3 litres of 0.03 M phos- 
phate buffer, pH 7.2, containing 20% glycerol, the 
carbonyl groups of the covalent enzyme coenzyme 
compound were reduced by treatment with 0.308 mg 
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sodium borohydride with a specific radioactivity of 
614 mCi/mmol, from CEA France. After standing 
for 36 h at room temperature the protein was preci- 
pitated by adding 10 ml 10% trichloroacetic acid and 
collected by centrifugation. The protein was dissolved 
in 5 ml 8 M urea which was adjusted to pH 8 by 
diluted ammonia and dialysed against water until the 
radioactivity of the protein did not further decrease. 
The sulphhydrylgroups were transferred into car- 
boxymethyl derivatives by treatment with 1 mM iodo- 
acetate [lo] and the excess of iodoacetate removed 
by dialysis 5 h against 50 ml 8 M urea, pH 8.0. The 
labelled protein was hydrolysed completely after 2 1 h 
in 6 N HCl at 110°C. HCl and water were removed by 
freeze drying over potassium hydroxide. The labelled 
compounds were separated by an aminoacid analyser 
Technicon and identified by comparing the elution 
volume with that of the model compounds prepared 
by alkylating N-Q acetyl aminoacids with 1 -p-D- 
ribofuranosyl- [ 5-bromoacetyl-4-methylimidazole] -5’ 
phosphate, reduced with sodium borohydride and 
hydrolysed with 6 N HCl. After removing HCl, 
retention times on the aminoacid analyser were 
determined and compared with the retention times 
of the tritium-labelled fractions of the hydrolysed 
protein. Samples of stoichiometric analysis were 
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digested by a-chymotrypsin. The digest was lyophilized 
and the chymotryptic peptides were separated by 
paper electrophoresis at pH 6.5 and pH 3.5. The 
labelled peptides were detected by autoradiography 
and scanning with a Panax scanner. The labelling was 
determined quantitatively after combustion of the 
protein on the electrophoresis paper in an Oximat 
Intertechnique, or after elution of the protein from 
the paper, in a Packard 3320 spectrometer. The 
scintillation solution was prepared according to 
Butler [ 111. The dissociation constant of the enzyme 
inactivator complex was determined as described 
previously [7]. 
3. Results 
The coenzyme analogue nicotinamide- [ 5-acetyl-4- 
methylimidazole] dinucleotide acts as hydrogen 
acceptor with 17 /3-estradiol dehydrogenase. The 
K, value is 7 mM and the turnover number 640 mol/ 
min. With NAD’ the KM value is 0.02 mM and the 
turnover number 272. The coenzyme analogue 
nicotinamide-[5-bromoacetyl-4-methylimidazole] 
dinucleotide is active as a hydrogen acceptor in the 
oxidation of the substrate too. The reactive bromo- 
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Fig.1. Double reciprocal plot l/k,bs versus l/c of the inactivation reaction. The intercept at the axis of abscisses corresponds to 
-l/KD and that of the ordinate to l/k,. 
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acetyl group of the analogue inactivates the enzyme. 
The dissociation constant K, of the reversible com- 
plex, which is formed at first, is 7 mM and in the 
same magnitude as the KM of the non brominated 
analogue both determined at pH 7.0. (fig.1). The 
inactivation rate k2 is 0.017 min-r [7]. The incorpo- 
ration of 2.2 mol 14C-labelled inactivator into 1 mol 
dimer (mol. wt. 72 000) was observed (fig.2). In 
presence of 0.1 mM estradiol, the incorporation of 
2.1 mole of the analogue into 1 mole enzyme dimer 
was observed. The presence of substrate effects a 
small increase of the inactivation velocity, but 0.05 
mM NADP’ completely protects the enzyme against 
inactivation by nicotinamide- [ 5-bromoacetyl-4- 
methylimidazole] dinucleotide (fig.3). The optical 
properties of the modified enzyme after reduction 
of the pyridinium system by sodium hyposulphite, 
are similar to that of the binary complex formed by 
dihydronicotinamide-[5-acetyl-4-methylimidazole] 
dinucleotide and the enzyme. After chymotryptic 
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Fig.3. Inactivation rate of 17 p-estradiol dehydrogenase. (1) In presence of 5 mM nicotinamide-[S-bromoacetyWmethylimidazole] 
dinucleotide. (2) In presence of 5 mM nicotinamide-[5-bromoacetyl-4-methylimidazole] dinucleotide and 0.1 mM estradiol. (3) 
In presence of 5 mM nicotinamide-[S-bromoacetyl-4-methylimidazole] dinucleotide and 0.05 mM NADP+. 
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Fig.2. Plot of residual enzyme activity (%) against N (N= 
moles of “C-labelled inactivator covalently linked per mole 
of enzyme dimer). 
digestion of the enzyme completely inactivated by 
“C-labelled nicotinamide-[5-bromoacetyl-4-methyl- 
imidazole] dinucleotide 3 cysteine containing pep- 
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tides showed changes in mobility in the electric field 
at pH 6.5 and pH 3.5. The three peptides are labelled 
to about the same extent. Acid hydrolysis of the 
inactivated and sodium [3H] borohydride treated 
enzyme yields a tritium labelled compound, which 
has the same elution volume on the aminoacid 
analyser as a model compound formed by N-a-acetyl 
cysteine and 1-@D-ribofuranosyl- [5-bromoacetyl-4- 
methylimidazole] -5’-phosphate and treated as 
described in Materials and methods. But the main 
radioactivity was recovered from the column together 
with ammonia. 
4. Discussion 
The alkylating coenzyme analogue nicotinamide- 
[5-bromoacetyl4-methylimidazole] dinucleotide acts 
as coenzyme in assay with estradiol dehydrogenase, it
combines with the enzyme like NAD+ and alkylates 
aminoacid residues at the active center. These residues 
seem to be in the coenzyme binding site, since NADP’ 
strongly protects against inactivation while the pre- 
sence of estradiol caused a small acceleration of the 
inactivation rate. The incorporation of 1 mol inacti- 
vator into 1 mol enzyme subunit agrees with the 
number of active sites per subunit [l-5] . The optical 
properties after treatment with sodium hyposulphite 
are similar to that of the binary complex formed 
with dihydronicotinamide-[5-acetyl-4-methylimidazole] 
dinucleotide and the enzyme. The alkylated residue 
was determined as the sulphydryl group of cysteine. 
It is possible that more than one of these residues are 
located at the active site of the enzyme and are 
involved in the catalytic process or coenzyme binding. 
‘This possibility is indicated by the separation of three 
labelled peptides after enzymatical digestion. The 
stoichiometry of the inactivation, 1 mole inactivator/ 
1 mole enzyme monomer, suggests that these cysteine 
residues are located at the active site possibly in such 
a way that the alkylation of one cysteine by the 
coenzyme analogue impairs the coenzyme binding 
and therefore the alkylation of the other residues. 
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